Like Forte Research Systems

announced 9/6/2019 via BNC Analysis

Advarra, will acquire Forte Research Systems

synopsis: Advarra, the premier provider of institutional review board, institutional biosafety committee, and research quality and compliance consulting services, will acquire Forte, the industry's leading provider of standards-based clinical research technology solutions for major academic medical centers, cancer centers, and health systems.
buyer parent: Genstar Capital LLC
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target parent: Primus
target: Forte Research Systems
Forte provides software and services in the critical areas of clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems. Forte's flagship Clinical Trial Management System, OnCore manages clinical research data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$24.62)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
closed 1/27/2015 via PR Newswire

genae, acquired e-novex

synopsis: genae, a global Contract Research Organization (CRO) and services provider for the medical industries, announced the acquisition of e-novex, a leading provider of electronic data tools that change medical research. e-novex' proprietory Electronic Data Capture (EDC) technology is widely adopted by various types of medical research organizations.
buyer: genae
genae is involved in the development and commercialization of medical devices, biologics and therapies that change medical practice. As a full service CRO and innovative services provider for the medical industries, genae aims at improving health and quality of life. "
target: e-novex
e-novex is a certified web technology company that provides electronic data tools that facilitates medical research. e-capture.net is an intuitive and user-centric EDC platform that features easy data entry, complex validation rules and flexible reporting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/17/2017 via BNC Analysis

Roche Ltd, will acquire Viewics, Inc.

synopsis: Roche announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. The Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond, pioneering a new way in extracting, cleansing, transforming and augmenting data.
buyer: Roche Ltd
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. "
target: Viewics, Inc.
California-based Viewics Inc. is a software company that focuses on laboratory business analytics. The Viewics solution allows for efficient integration of big data from a variety of IT systems in the laboratory and beyond.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2012 via PR Newswire

ERT, acquired invivodata, Inc.

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations (CROs), announced the acquisition of invivodata, Inc, a leading provider of electronic Patient Reported Outcomes (ePRO) solutions and Consulting services, based in Pittsburgh, PA.
buyer parent: Genstar Capital LLC
buyer: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives. "
target: invivodata, Inc.
invivodata is a fully-integrated Clinical Outcome Assessments organization delivering regulatory-proven strategic consulting and practical electronic solutions to biopharmaceutical companies who depend upon patient-centered research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/15/2018 via Company Press Release

NovaQuest, acquired Clinical Ink

synopsis: Clinical Ink, the pioneering provider of eSource and next-generation ePRO/eCOA solutions for clinical development, announced that the private equity team at NovaQuest Capital Management has acquired a majority of the outstanding shares of the company from existing investors and provided a substantial infusion of additional growth capital.
buyer: NovaQuest
NovaQuest Capital Management is a leading investor in life sciences and healthcare through their BioPharma and Private Equity strategies. NovaQuest Capital Management manages over $1.6 billion through two platforms: BioPharma and Private Equity. "
target: Clinical Ink
Clinical Ink provides eSource solutions for the clinical trials industry. It offers SureSource, an electronic source solution that allows users to record comments, explanations, and validated source data on protocol specific eSource documents, as well as captures the data required by the protocol.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/7/2019 via GlobeNewswire

Tabula Rasa Healthcare, acquired DoseMe

synopsis: Tabula Rasa HealthCare, Inc., a healthcare technology company advancing the field of medication safety, has acquired DoseMe. DoseMe is the developer of DoseMeRx, an advanced precision dosing tool to help physicians and pharmacists accurately dose patients’ high-risk parenteral medications. DoseMe is based in the US and Australia.
buyer: Tabula Rasa Healthcare (TRHC:$204.27)
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize patient outcomes, lower healthcare costs and improve organizational performance. "
target: DoseMe
DoseMe is the developer of DoseMeRx, an advanced precision dosing tool to help physicians and pharmacists accurately dose patients’ high-risk parenteral medications based on individual needs, resulting in significant improvements to mortality, risk, and patient outcomes.
price ($mm)
$21
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/4/2016 via BusinessWire

Rx30 Pharmacy System, acquired vMEDEX, Inc.

synopsis: Transaction Data Systems, Inc., doing business as Rx30, announced that Rx30 has completed its acquisition of vMEDEX. vMEDEX has been a valued integration partner over the past 3 years, demonstrating an innovative approach to providing advanced clinical services functionality.
buyer: Rx30 Pharmacy System
Rx30 is a total Pharmacy Management Software application that truly acts as the hub for all pharmacy management activities, including prescription dispensing, fully automated refills and reminders, workflow management, adherence management, document management, smart phone/web refills and more. "
target: vMEDEX, Inc.
vMEDEX is a healthcare Software as a Service company. Healthcare practitioners are able to care for more patients with greater quality and consistency using vMEDEX powered solutions. vMEDEX deliver expert healthcare assistance when and where it is needed most to protect those most vulnerable.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/11/2018 via Company Press Release

Genpact Ltd, will acquire Commonwealth Informatics Inc.

synopsis: Genpact, a professional services firm focused on delivering digital transformation, announced that it has signed a definitive agreement to acquire Commonwealth Informatics, Inc. (CI), a market-leading provider of cloud-based drug safety analytics products and services for medical research and healthcare delivery headquartered near Boston, Mass.
buyer: Genpact Ltd (G:$2,899.86)
Genpact is a global professional services firm that makes business transformation real. They drive digital-led innovation and digitally-enabled intelligent operations for their clients. They think with design, dream in digital, and solve problems with data and analytics. "
target: Commonwealth Informatics Inc.
Commonwealth Informatics provides cloud-based drug safety analytics products and services for medical research and healthcare delivery. Their Commonwealth Vigilance Workbench consists of integrated modules used by pharmaceutical and biotech companies, government agencies, and healthcare providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/9/2019 via Company Press Release

Express Scripts Inc., acquired Verity Solutions

synopsis: Verity Solutions, an award-winning leader in software and services developed for administration of the federal 340B drug pricing program, has been acquired by Express Scripts, a Cigna company. Verity Solutions simplifies the complex process of maintaining 340B PROGRAM compliance resulting in critical 340B cost savings for their customers.
buyer parent: CIGNA Corporation
buyer: Express Scripts Inc. (ESRX:$100,275.80)
Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services. "
target: Verity Solutions
Verity Solutions is an award-winning leader in software and services developed for administration of the federal 340B drug pricing program. Verity Solutions simplifies the complex process of maintaining 340B PROGRAM compliance resulting in critical 340B cost savings for their customers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/13/2019 via BNC Analysis

Allscripts, acquired ZappRx

synopsis: Medical software company Allscripts has bought ZappRx, a start-up that aimed to modernize how people access prescription medicines. ZappRx was founded in 2012 in Boston, Mass. ZappRx specializes in helping people access the class of so-called specialty medicines, which includes expensive and high-complex or high-cost interventions.
buyer: Allscripts (MDRX:$1,748.29)
Allscripts is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Their solutions connect people, places and data across an Open, Connected Community of Health. Connectivity empowers caregivers to deliver care for healthier populations. "
target: ZappRx
ZappRx is a digital health company offering a prescription and prior authorization (“PA”) platform; their goal is to streamline and increase efficiencies in the way specialty medications reach patients. ZappRX provides a secure, collaborative online platform to improve patients’ access to treatment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/25/2019 via BNC Analysis

Netmeds Marketplace Limited, acquired KiViHealth

synopsis: Online pharmacy NetMeds Marketplace Pvt. Ltd has acquired health-tech startup KiViHealth. KiViHealth is a clinic management platform that allows doctors to generate digital prescriptions. It also offers electronic historical health records storage. The KiViHealth app also provides an appointment booking module and a patient engagement tool.
buyer: Netmeds Marketplace Limited
NetMeds lets users order their medicines via its portal and mobile app by uploading their prescriptions. A team of qualified pharmacists verifies the prescription for validity and prescribes the appropriate dosage accordingly. NetMeds is based in Chennai, India. "
target: KiViHealth
KiViHealth is a clinic management platform that allows doctors to generate digital prescriptions. It also offers electronic historical health records storage. The KiViHealth app also provides an appointment booking module and a patient engagement tool, along with billing invoicing solutions.
price ($mm)
$10
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/10/2017 via Market Wire

Canada House Wellness Group Inc., acquired Knalysis Technologies Inc.

synopsis: Canada House Wellness Group Inc. is pleased to announce that it has acquired 100% of Knalysis Technologies Inc. Knalysis creates tools for better cannabis health outcomes by its innovative software that seamlessly links physicians, providers, and patients, offering a global approach to reporting, monitoring and care.
buyer: Canada House Wellness Group Inc. (CNSX:CHV:$4.92)
Canada House is the parent company of Marijuana for Trauma and Abba Medix Corp. The Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated medical cannabis marketplace. "
target: Knalysis Technologies Inc.
Knalysis creates tools for better cannabis health outcomes by its innovative software that seamlessly links physicians, providers, and patients, offering a global approach to reporting, monitoring and care.
price ($mm)
$1.01
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/16/2017 via BusinessWire

First DataBank, Inc., acquired Polyglot Systems, Inc.

synopsis: First Databank, Inc., the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions, announced it has acquired Morrisville, North Carolina-based Polyglot Systems, Inc., creator of the Meducation product line of simplified patient medication instructions.
buyer parent: The Hearst Corporation
buyer: First DataBank, Inc.
First DataBank, Inc., part of the Hearst Health network, is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions. FDB enables their information system developer partners to deliver valuable, useful, and differentiated solutions. "
target: Polyglot Systems, Inc.
Polyglot Systems is an industry-leading provider of software-based communication solutions designed to reduce language barriers and improve medication literacy in health care. Their software is designed to improve patient understanding, thereby improving health and increasing patient satisfaction.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/14/2011 via PR Web

DrFirst, Inc., acquired AdherenceRx

synopsis: DrFirst.com Inc., the nation’s leading e-prescribing software company, has announced its acquisition of AdherenceRx, LLC, a move that forms DrFirst’s new Patient Innovation division.
buyer: DrFirst, Inc.
Founded in 2000, DrFirst's flagship product, Rcopia, is the nation's leading full-featured stand-alone electronic prescription management system. DrFirst understands that healthcare is an interconnected environment between physician practices, IPAs, hospitals, health plans, pharmacies and others. "
target: AdherenceRx
AdherenceRx strives to be the leading source of medication adherence techniques & solutions to the Healthcare Industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/5/2008 via BusinessWeek

Phase Forward, acquired Clarix LLC

synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has acquired privately held Clarix LLC, an innovative provider of fully Web-integrated interactive response technology (IRT), for $40 million in cash.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
target: Clarix LLC
Clarix LLC is a company providing an innovative suite of eClinical software products including the most advanced, fully Web-integrated IRT in the industry. Clarix applications are designed for rapid deployment, flexibility and advanced real-time reporting capability.
price ($mm)
$34
rev ($mm)
$3
EBITDA ($mm)
EV / rev
14.6x
EV / EBITDA
closed 3/20/2012 via BusinessWire

Pharmaceutical Strategies Group, LLC, acquired Artemetrx

synopsis: Pharmaceutical Strategies Group, LLC, America’s largest independent pharmacy benefits consulting firm, has closed on its acquisition of Artemetrx Health Resources. Artemetrx offers data analytic tools and clinical programs that integrate pharmacy, medical, and other healthcare information.
buyer: Pharmaceutical Strategies Group, LLC
Pharmaceutical Strategies Group, LLC assists plan sponsors and other payors, Taft-Hartley Unions, large employers, and health systems in designing, implementing, and managing programs that maximize the value and impact of pharmaceuticals in their population. "
target: Artemetrx
At the core of the Artemetrx service offering is a robust proprietary data aggregation engine that combines behavioral, medical, dental, vision, lab, and prescription drug data to provide a comprehensive view of health-related utilization and expenditures.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/6/2019 via BusinessWire

ZYUS, acquired Revon Systems

synopsis: ZYUS Life Sciences Inc. has acquired Revon Systems, Inc., a healthcare technology company that developed a data collection platform integrating mobile technology and connected devices with health care services and therapies. ZYUS will use Revon’s platform as a digital therapeutic patient interface and a real-time data collection platform.
buyer: ZYUS
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of cannabinoid-based therapeutics and product candidates. ZYUS delivers high-quality oils, gel-caps, topical creams, and other cannabinoid-based therapeutics and product candidates to patients. "
target: Revon Systems
Revon is a healthcare technology company that developed a data collection platform that integrates mobile technology and connected devices with health care services and therapies. The platform supports data collection for investigating the performance of pharmaceutical and other interventions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/12/2016 via BusinessWire

DrFirst, Inc., acquired iPrescribe

synopsis: DrFirst, a leading provider of electronic prescribing and secure texting solutions for healthcare providers, announced it has acquired the assets of iPrescribe.net, a mobile e-prescribing application for iOS and Android devices. iPrescribe allows medical professionals to avoid Medicare Incentive Program penalties.
buyer: DrFirst, Inc.
DrFirst pioneers electronic prescribing, medication management and secure care collaboration solutions that enhance the doctor-patient point of encounter, optimize provider access to patient information, inform the doctor’s clinical view of patients and improve care delivery and clinical outcomes. "
target: iPrescribe
iPrescribe is a complete e-prescribing application that will save time and improve clinical workflow efficiency. iPrescribe allows medical professionals to avoid Medicare Incentive Program penalties. iPrescribe is certified for use over the SureScripts® network.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/13/2017 via BusinessWire

Genoa Healthcare, acquired Medication Management Systems, Inc.

synopsis: The nation’s leading behavioral health pharmacy and telepsychiatry company, Genoa, a QoL Healthcare Company, announced the acquisition of Medication Management Systems, Inc., a Minneapolis-based provider of comprehensive medication therapy management services and technology for complex high-risk patients.
buyer: Genoa Healthcare
Genoa, a QoL Healthcare Company, has been serving the behavioral health community for more than 15 years. The company provides pharmacy and telepsychiatry services to more than 550,000 individuals annually in 48 states & the District of Columbia, filling more than 12 million prescriptions per year. "
target: Medication Management Systems, Inc.
Medication Management Systems, Inc. provides comprehensive, patient–centered medication management services and technology to improve medication therapy by identifying and resolving patients’ medication therapy problems.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/6/2019 via BNC Analysis

Advarra, will acquire Forte Research Systems

synopsis: Advarra, the premier provider of institutional review board, institutional biosafety committee, and research quality and compliance consulting services, will acquire Forte, the industry's leading provider of standards-based clinical research technology solutions for major academic medical centers, cancer centers, and health systems.
buyer parent: Genstar Capital LLC
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target parent: Primus
target: Forte Research Systems
Forte provides software and services in the critical areas of clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems. Forte's flagship Clinical Trial Management System, OnCore manages clinical research data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/6/2019 via BNC Analysis

Advarra, will acquire Forte Research Systems

synopsis: Advarra, the premier provider of institutional review board, institutional biosafety committee, and research quality and compliance consulting services, will acquire Forte, the industry's leading provider of standards-based clinical research technology solutions for major academic medical centers, cancer centers, and health systems.
buyer parent: Genstar Capital LLC
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target parent: Primus
target: Forte Research Systems
Forte provides software and services in the critical areas of clinical trial management, clinical data management, and research administration for cancer centers, academic medical centers, and health systems. Forte's flagship Clinical Trial Management System, OnCore manages clinical research data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/6/2019 via Company Press Release

Advarra, acquired Kinetiq

synopsis: Advarra, the premier provider of institutional review board (IRB) and research quality and compliance consulting services, acquired Quorum’s research and technology consulting division, Kinetiq. Kinetiq delivers innovative solutions for human subject protection and compliance in clinical research.
buyer parent: Linden Capital Partners
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target parent: Quorum Review IRB
target: Kinetiq
Kinetiq is a consulting and technology division of Quorum Review IRB that delivers innovative solutions for human subject protection and compliance in clinical research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/21/2013 via BusinessWire

Audax Group, acquired Chesapeake Research Review

synopsis: Audax Group announced it has completed the recapitalization of Chesapeake Research Review, Inc. Chesapeake is a leading provider of independent institutional review board (“IRB”) services to major pharmaceutical, biotech and medical device companies, universities, academic medical centers, and hospital systems.
buyer: Audax Group
Audax Group, founded in 1999, is a leading investor in lower-middle market companies. With offices in Boston and New York, Audax has over $5 billion in assets under management in its Private Equity, Mezzanine, and Senior Debt businesses. "
target: Chesapeake Research Review
Chesapeake Research Review, Inc. provides human research protections services. It offers institutional review board services & human research protections consultation, including strategic & operational, IRB consultation services; ethical, scientific & applied bioethics review, education & auditing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/9/2019 via BNC Analysis

Genstar Capital LLC, acquired Advarra

synopsis: Genstar Capital, a private equity firm focused on investments in financial services, healthcare, industrial technology, and software industries, has acquired Advarra, a leading provider of institutional review board, institutional biosafety committee, and research quality and compliance solutions that are critical to the drug development process.
buyer: Genstar Capital LLC
Genstar Capital is a leading private equity firm that actively invests in high quality companies. Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. "
target parent: Linden Capital Partners
target: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/22/2016 via PR Newswire

The WIRB-Copernicus Group, acquired CenterWatch, Inc.

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality and efficiency of clinical research, announced its acquisition of CenterWatch, the leading provider of clinical trial industry news and information. CenterWatch provides clinical trials information to clinical research professionals.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
target: CenterWatch, Inc.
CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 5/5/2010 via Company Press Release

Kenneth Getz, acquired CenterWatch, Inc.

synopsis: Ken Getz, the founder of CenterWatch—an industry-leading clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information.
buyer: Kenneth Getz
Ken Getz founded CenterWatch in 1994 and established the company as a leading provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. "
target parent: Wicks Group of Companies
target: CenterWatch, Inc.
CenterWatch is a trusted source and global destination of clinical trials information for both professionals and patients. CenterWatch provides a wide variety of information services including grant leads for investigative sites, data about the global clinical trials industry and more.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2007 via Berkery

Jobson Medical Information LLC, acquired CenterWatch, Inc.

synopsis: The Thomson Corporation announced the sale of CenterWatch to Jobson Medical Information, a portfolio company of The Wicks Group, LLC. CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
buyer parent: The Wicks Group of Companies, L.L.C.
buyer: Jobson Medical Information LLC
Jobson Medical Information is a leading specialty healthcare communications, publishing, and medical education company. Jobson Medical Information produces a broad range of publications, educational programs, enduring educational materials, live events, symposia and websites. "
target parent: Thomson Corporation
target: CenterWatch, Inc.
CenterWatch is a trusted source and global leader in providing proprietary data and information about clinical trials to both professionals and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/26/2015 via Company Press Release

Inovalon, Inc., will acquire Avalere Health LLC

synopsis: Inovalon, a leading technology company providing cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
buyer: Inovalon, Inc. (INOV:$449.36)
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. "
target: Avalere Health LLC
Avalere Health, Inc. is a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
price ($mm)
$140
rev ($mm)
$47
EBITDA ($mm)
EV / rev
3.0x
EV / EBITDA
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 7/10/2007 via

Providence Equity Partners Inc., acquired Decision Resources, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced today that Providence Equity Partners, a leading private equity firm with more than $21 billion under management, will acquire majority control of the Company.
buyer: Providence Equity Partners Inc.
Providence Equity Partners Inc. is a private investment firm specializing in equity investments in communications and media companies around the world. The principals of Providence Equity manage funds with approximately $21 billion in equity commitments. "
target parent: Boston Ventures Management, Inc.
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/6/2004 via PR Newswire

Boston Ventures Management, Inc., Castanea Partners, acquired Decision Resources, Inc.

synopsis: Castanea Partners and Boston Ventures Limited Partnership VI today announced the recapitalization of Decision Resources, Inc., with a total transaction value of $58 million. The Waltham, Massachusetts-based company is best known for its therapeutically-focused analyses of global pharmaceutical and biotechnology markets.
buyer: Boston Ventures Management, Inc.
buyer: Castanea Partners
Boston Ventures Management, LLC is a private equity firm that has been an active investor and financial partner to management teams in the media, entertainment, publishing and information and communications sectors since 1983, earning the firm a franchise position in the private equity community. "
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
$58
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/16/2015 via BNC Analysis

Sudler & Hennessey, acquired System Analytic Ltd.

synopsis: Sudler & Hennessey, has acquired a majority stake in System Analytic for an undisclosed sum. Sudler is a global healthcare marketing and communications network, while London-based System Analytic’s database and online tools enable pharmaceutical companies to identify, map and engage key opinions leaders across a broad range of medical fields.
buyer parent: WPP Group, plc
buyer: Sudler & Hennessey
Sudler & Hennessey is one of the world's leading healthcare communications firms, developing strategic promotional and educational programmes for a broad array of healthcare brands. "
target: System Analytic Ltd.
System Analytic Ltd. owns and operates a database and online tools to help pharmaceutical companies to identify and engages opinion leaders. The company was incorporated in 2006 and is based in London, United Kingdom.
price ($mm)
rev ($mm)
$3
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/4/2015 via PR Newswire

Precision for Value, acquired Redwood Outcomes

synopsis: Precision for Value, a company that supports commercial excellence for global pharmaceutical and life sciences clients through the demonstration and communication of product value and outcomes, announced its acquisition of Redwood Outcomes, a leading international health economics and outcomes research company.
buyer parent: Precision for Medicine
buyer: Precision for Value
Precision for Value supports excellence for global pharmaceutical and life sciences clients through the communication of product value and outcomes. The Precision for Value teams provide clients with services of industry knowledge, demonstrated analytics proficiency, and communications prowess. "
target: Redwood Outcomes
Redwood Outcomes is a Health Economics & Outcomes Research firm. They aim to advance and apply the science of evidence synthesis, integration, and communication to optimize health care decision-making.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/8/2017 via GlobeNewswire

PRA Health Sciences, will acquire Symphony Health Solutions

synopsis: PRA Health Sciences, Inc. (“PRA”), a leading clinical research organization, announced it has signed a definitive agreement to acquire Symphony Health Solutions Corporation (“Symphony Health”), a privately-held best-in-class provider of data, analytics and consulting solutions to the life sciences market.
buyer parent: Kohlberg Kravis Roberts & Co.
buyer: PRA Health Sciences (PRAH:$1,698.48)
PRA Health Sciences is one of the world’s leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. "
target parent: Symphony Technology Group
target: Symphony Health Solutions
Symphony Health Solutions is a leading provider of high-value data, analytics, and technology solutions for biopharmaceutical manufacturers, healthcare providers, and payers. Symphony Health derived data improves health management decisions, and helps clients drive revenue growth.
price ($mm)
$530
rev ($mm)
$200
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
announced 6/15/2016 via PR Newswire

The WIRB-Copernicus Group, will purchase Clinical Trial Applications from karmadata

synopsis: WIRB-Copernicus Group, one of the world's leading providers of solutions that measurably improve the quality of clinical research, will acquire from karmadata a suite of proprietary applications designed to facilitate the management of clinical trial data. karmadata is the market leader in clinical trial database and decision support applications.
buyer parent: Arsenal Capital Partners
buyer: The WIRB-Copernicus Group
WIRB-Copernicus Group (WCG) is one of the world's leading providers of solutions that measurably improve the quality and efficience of clinical research. WCG enables biopharmaceutical companies, Clinical Services Organizations and institutions to accelerate the delivery of new treatments. "
seller: karmadata
Karmadata is able to standardize and link the world's healthcare data ranging from leading open data sources to priva pharmacy and medical claims. Its propriety applications are designed to facilitate the management of clinical trial data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/31/2006 via BNC Analysis

Informa plc, acquired Citeline

synopsis: Informa plc, the leading provider of business intelligence and strategic services to the global telecoms and media markets has acquired Citeline, Inc., the leading provider of global clinical trials intelligence to the pharmaceutical industry.
buyer: Informa plc (LSE:INF:$3,003.74)
Informa plc is the leading international provider of specialist information and services for the academic and scientific, professional and commercial business communities. "
target: Citeline
Citeline developes innovative intelligence solutions for pharmaceutical and biotechnology companies. Citeline enhances the competitive position of its clients by providing actionable information about competitors' worldwide clinical development activities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2011 via Company Press Release

ICON Plc, acquired Oxford Outcomes

synopsis: ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced the expansion of its Late Phase and Outcomes Research services through the acquisition of Oxford Outcomes, a leading international health outcomes consultancy.
buyer: ICON Plc (ICLR:$1,541.91)
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. "
target: Oxford Outcomes
Headquartered in Oxford, UK, and with offices in the USA and Canada, Oxford Outcomes provides specialist services in the areas of patient reported outcomes (PRO), health economics, epidemiology and translation and linguistic validation.
price ($mm)
$28*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Forte Research Systems


read more

Forte Research Systems

OmniComm Systems, Inc.

e-novex

Viewics, Inc.

invivodata, Inc.

Clinical Ink

DoseMe

vMEDEX, Inc.

Commonwealth Informatics Inc.

Verity Solutions

ZappRx

KiViHealth

Knalysis Technologies Inc.

Polyglot Systems, Inc.

AdherenceRx

Clarix LLC

Artemetrx

Revon Systems

iPrescribe

Medication Management Systems, Inc.

read more

Forte Research Systems

read more

Forte Research Systems

Advarra

Kinetiq

Chesapeake Research Review

read more

Advarra

CenterWatch, Inc.

ERT

ERT

CenterWatch, Inc.

CenterWatch, Inc.

Context Matters

Avalere Health LLC

Abacus International

Decision Resources Group

Decision Resources, Inc.

Decision Resources, Inc.

System Analytic Ltd.

Cognitive Drug Research, Ltd.

Redwood Outcomes

Symphony Health Solutions

karmadata

Citeline

Oxford Outcomes

Aureus Sciences

Geography
Matching Companies
Ticker: OTCPK:OMCM
 
 
 
 
 
 
 
 
OmniComm Systems, Inc.
OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments.
year
2019
rev ($mm)
$24.62
EBITDA ($mm)
$1.80
EBIT ($mm)
$1.31
Net Income ($mm)
$1.83
Employees
175
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: MDSO
 
 
 
 
 
 
 
 
Medidata Solutions Worldwide
Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion.
year
2019
rev ($mm)
$660.00
EBITDA ($mm)
$80.64
EBIT ($mm)
$42.88
Net Income ($mm)
$52.74
Employees
1998
  • drill down
  • watch
Ticker: OM:RTC
 
 
 
 
 
 
 
 
Rethinking Care AB
Rethinking Care AB
Rethinking Care introduces a holistic concept in nursing & health, based on 3 interacting spheres of activity - "Software as a service", "Care as a service" & "Health as a service", based on a high level of competence in nursing & healthcare services as well as IT tools developed for health care.
year
2016
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: INOV
 
 
 
 
 
 
 
 
Inovalon, Inc.
Inovalon, Inc.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape.
year
2017
rev ($mm)
$449.36
EBITDA ($mm)
$75.91
EBIT ($mm)
$27.16
Net Income ($mm)
$34.82
Employees
2119
  • drill down
  • watch
Ticker: DB:COP
 
 
 
 
 
 
 
 
CompuGroup Medical AG
CompuGroup Medical AG
CompuGroup Medical is a leading global eHealth provider. Their software and communications solutions assist doctors, dentists, hospitals, pharmacists, associations, networks and other service providers with workflow, diagnosis and therapy.
year
2018
rev ($mm)
$830.72
EBITDA ($mm)
$205.39
EBIT ($mm)
$158.54
Net Income ($mm)
$97.39
Employees
4572
  • drill down
  • watch
Ticker: AIM:EMIS
 
 
 
 
 
 
 
 
EMIS Group PLC
EMIS Group PLC
Egton Medical Information Systems Ltd (EMIS) is the UK's market leading primary care software provider with more than 39 million patient records entrusted to its systems. Its aim is to make good quality, timely patient information available any time, any where through interoperable systems.
year
2018
rev ($mm)
$216.76
EBITDA ($mm)
$33.15
EBIT ($mm)
$21.39
Net Income ($mm)
$14.24
Employees
2046
  • drill down
  • watch
Ticker: EVH
 
 
 
 
 
 
 
 
Evolent Health
Evolent Health
Evolent partners with leading health systems to drive value-based care transformation. By providing clinical, analytical and financial capabilities, Evolent helps physicians and health systems achieve superior quality and cost results.
year
2016
rev ($mm)
$212.24
EBITDA ($mm)
($39.30)
EBIT ($mm)
($52.25)
Net Income ($mm)
Employees
946
  • drill down
  • watch
Ticker: MTBC
 
 
 
 
 
 
 
 
Medical Transcription Billing, Corp.
Medical Transcription Billing, Corp.
MTBC (Medical Transcription Billing, Corp) is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers, revenue cycle management companies and software vendors.
year
2016
rev ($mm)
$21.30
EBITDA ($mm)
($1.14)
EBIT ($mm)
($5.80)
Net Income ($mm)
Employees
1600
  • drill down
  • watch
Ticker: TSXV:BIO
 
 
 
 
 
 
 
 
AioCare
AioCare
AioCare, formerly known as Biosign Technologies, develops and sells cloud-based healthcare software products that address the needs in clinic management, home care operations, health monitoring and virtual care management. Their cutting edge technology is transforming Healthcare delivery in Germany.
year
2015
rev ($mm)
$0.38
EBITDA ($mm)
($3.04)
EBIT ($mm)
($3.43)
Net Income ($mm)
$1.21
Employees
16
  • drill down
  • watch
Ticker: TSXV:MSD
 
 
 
 
 
 
 
 
Moseda Technologies, Inc.
Moseda Technologies, Inc.
Moseda Technologies is a software developer of secure mobile health and telemedicine solutions for the healthcare sector. Their SmartCare solution integrates the latest in mobile, wearables and SaaS technology to provide increased levels of efficiency and reduction in redundant administrative tasks.
year
2015
rev ($mm)
$0.02
EBITDA ($mm)
($1.86)
EBIT ($mm)
($1.86)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: OTCPK:SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc
Scrypt builds secure cloud-based workflow management and collaboration tools for regulated industries. They help businesses operating in regulated industries improve document workflow and regain valuable time while protecting business-critical information.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.86)
EBIT ($mm)
($0.92)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: HAXS
 
 
 
 
 
 
 
 
Healthaxis, Inc.
Healthaxis, Inc.
HealthAxis Group is simultaneously the most experienced and modern SaaS-based supplier of benefit platform systems. The comprehensive suite offered by HealthAxis helps organizations address compliance, increase administrative efficiency, lower cost, and improve quality.
year
2007
rev ($mm)
$16.03
EBITDA ($mm)
$0.27
EBIT ($mm)
($0.86)
Net Income ($mm)
Employees
73
  • drill down
  • watch
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch